Marché des excipients pharmaceutiques en Amérique du Nord – Tendances et prévisions du secteur jusqu’en 2030

Analyse et perspectives du marché des excipients pharmaceutiques en Amérique du Nord

Les excipients pharmaceutiques jouent un rôle majeur dans la formulation et le développement des médicaments. Ces substances sont constituées d'autres substances que le médicament ou le promédicament pharmacologiquement actif. Les excipients pharmaceutiques assurent une administration efficace du médicament au site cible. Ces molécules empêchent la libération trop précoce du médicament lors de son assimilation et améliorent son efficacité. Certains excipients pharmaceutiques favorisent l'intégration du médicament, ce qui stimule son absorption dans la circulation sanguine.

Data Bridge Market Research analyse que le marché nord-américain des excipients pharmaceutiques devrait atteindre la valeur de 6 894,31 millions USD d'ici 2030, à un TCAC de 6,6 % au cours de la période de prévision. La fonctionnalité représente le segment de type le plus important du marché en raison de la demande rapide de solutions et de services informatiques en Amérique du Nord. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.

Définition du marché des excipients pharmaceutiques en Amérique du Nord

Pharmaceutical excipients involve everything in a drug except the active pharmaceutical ingredients. These molecules don’t possess medicinal properties and are ultimately used to enhance the drug's physiological absorption.  Pharmaceutical excipients are inert, allowing the drug molecule to apply to patients in the right form. Traditionally pharmaceutical excipients were simple molecules, but technological innovation and increasing demand for novel drug delivery systems enhanced the pharmaceutical excipient's complexity.  Pharmaceutical excipients promote the patient’s drug acceptability and boost the drug's stability and bioavailability.

The future of excipients science and technology has changed and continues to change. Better progress has been made in such areas as harmonizing excipient pharmacopeial monographs and applying new analytical methods to characterize excipients better.

North America Pharmaceutical Excipients Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Rise in Generic Drug Production and Uses

According to the U.S. Food and Drug Administration (U.S. Food and Drug Administration). FDA) and the National Center for Biotechnology Information (NCBI), a generic drug is a drug that has been created to look like an approved brand-name drug that is available in dosage form, with safety, strength, route of administration, quality, and performance. After the drug's patent expires, the cost savings associated with conventional drug use are not immediately apparent. Generic drugs, like brand-name drugs, require competition in the generic drug market before reducing costs; two to three years after the loss of exclusivity, the price of a generic drug is usually 60-70% lower than that of a brand-name drug. Since India has the highest per capita spending, these generic drugs will save a lot of money that can be used for other health problems. Nationally, the use of generic drugs has increased significantly in recent years. The fact that cheap substitutes for branded drugs are a major reason likely to spur the growth of the pharmaceutical industry. The generic drug industry in the near future.

Thus, increasing demand for generic drugs and rising production are expected to drive the North America pharmaceutical excipients market growth. Also, the cost of generic drugs is less, which increases the use of generic drugs.

• The Surge in Demand for Excipients

Pharmaceutical excipients are substances in pharmaceutical dosage forms not for direct therapeutic use but to facilitate the manufacture, protection, support, or improvement of stability and availability. With the increased development of the North America pharmaceutical industry, excipients also have a light part. Recently, there has been an increasing demand for generic drugs, which has led to an increase in the excipients demand. In addition, there has been a sharp increase in cases of chronic diseases.

Excipients are inert substances, other than pharmaceutically active drugs, introduced into the manufacturing process or included in the dosage form of pharmaceutical products. Excipients are widely used in drug formulations to add bulk to solid formulations, provide long-term stability, and facilitate drug absorption. Furthermore, it also improves the product's overall safety or functional properties during use or storage.

Thus, wide uses of excipients in drug formulation and applications of excipients are expected to drive the North America pharmaceutical excipients market.

Restraint

• Increasing Regulatory Stringency Regarding The Approval of Drugs and Excipients

Generic drug approval rules are largely the same worldwide, with little difference in developing countries. This is because he is not required to undergo bioequivalence (BE) study in this part of the world to obtain generic drug approval. Governments must ensure consistent quality of all generic drugs, medical experts say. Only then will doctors be happy and confident in prescribing generic drugs. A major reason for physicians' (and even patients') lack of confidence in generic drugs has been the lack of strict regulatory requirements regarding the number of generic drugs and the number of impurities allowed.

Controlling the manufacture and distribution of excipients is now considered a top priority by regulators and drug manufacturers, as mixing excipients has resulted in adverse patient events. Furthermore, with the emergence of new excipients and delivery systems, better control of the quality and supply of pharmaceutical excipients has become increasingly important in the context of in vivo activity. Recognizing the important role of excipients in pharmaceutical dosage forms requires excipient suppliers to meet the quality requirements of the pharmaceutical industry, and the pharmaceutical industry, in general, must work to ensure the product's safety. The integrity of use or storage in the supply chain. Hence, the Increasing Regulatory Stringency Regarding the Approval of Drugs and Excipients is expected to restrain the North America pharmaceutical excipients market growth.

Opportunity

• Strategic Initiatives by Market Players

The rise in the pharmaceutical excipients market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for pharmaceutical excipients, and to cope with this demand, companies are building new manufacturing sites, among other strategic initiatives.

These strategic initiatives, such as product launches, acquisitions, agreements, and business expansion by the major market player, will boost the pharmaceutical excipients market growth and are expected to act as an opportunity for the North America pharmaceutical excipients market.

Challenge

• Associated Side Effects

Adverse effects due to pharmaceutical excipients in drug formulations are generally uncommon, but the potential for toxicity is increased at high mg per kg doses, especially in neonates and infants. Methyl and Propyl para-hydroxybenzoate (Parabens), Benzyl Alcohol, Sodium Benzoate, Benzoic Acid, and Propylene Glycol, among others, are some of the common pharmaceutical excipients that have reported side effects.

Pharmaceutical excipients are not always the inert substances that we presume. They are intolerant to an individual or, if not properly screened, can cause chemical changes in the drug, causing the side-effect. This can affect the demand for the excipient and is expected to act as a challenge for the North America pharmaceutical excipients market.

Post-COVID-19 Impact on North America Pharmaceutical Excipients Market

The pharmaceutical industry has been severely affected by the COVID-19 pandemic. Lockdowns imposed due to the epidemic have disrupted the supply of raw materials from manufacturing centers such as India and China. This slowed drug development and production, severely affecting companies that relied heavily on outsourcing. Initially, the entire pharmaceutical ecosystem was disrupted. In addition, regulatory agencies had to draft and draft new laws to ensure maximum patient safety after using drugs. After the shutdowns ended, the pharmaceutical industry gained steam, especially due to the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The growing demand for these drugs boosted the turnover of some companies.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology in the pharmaceutical excipients market.

Recent Developments

• In February 2022, Kerry Group Plc., the world’s leading taste and Nutrition Company, announced that it had made two significant biotechnology acquisitions that have expanded its expertise, technology portfolio, and manufacturing capabilities. The company has announced that it has acquired the leading biotechnology Innovation Company, c-LEcta, and Mexican-based enzyme manufacturer, Enmex. c-LEcta is a leading biotechnology innovation company specializing in precision fermentation, optimized bio-processing, and bio-transformation. Also, Enmex is a well-established enzyme manufacturer based in Mexico, supplying multiple bio-process solutions for food, beverage, and animal nutrition markets. This has helped the company to increase its revenue
• In September 2022, DFE Pharma, a North America leader in pharma- and nutraceutical excipient solutions, opened its new “Closer to the Formulator” (C2F), a Center of Excellence, in Hyderabad, India. C2F helped pharmaceutical companies to shorten the time from concept to finished commercial product through its expertise in all phases of pharmaceutical development. This has helped the company to showcase its progress

North America Pharmaceutical Excipients Market Scope

The North America pharmaceutical excipients market is segmented into functionality, dosage forms, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY

• Binders And Adhesives 
• Disintegrants 
• Coating Material 
• Coloring Agents
• Solubilizers
• Flavors
• Sweetening Agents
• Diluents
• Lubricants
• Buffers
• Emulsifying Agents
• Preservatives
• Antioxidants
• Sorbents
• Solvents
• Emollients
• Glidents
• Chelating Agents
• Antifoaming Agents
• Others

On the basis of functionality, the North America pharmaceutical excipients market is segmented into binders and adhesives, disintegrants, coating material, coloring agents, solubilizers, flavors, sweetening agents, diluents, lubricants, buffers, emulsifying agents, preservatives, antioxidants, sorbents, solvents, emollients, glidents, chelating agents, antifoaming agents, and others.

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM

• Solid
• Semi-Solid
• Liquid

On the basis of dosage forms, the North America pharmaceutical excipients market is segmented into solid, semi-solid, and liquid

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION

• Oral Excipients 
•  Topical Excipients 
•  Parenteral Excipients 
•  Other Pharmaceutical Excipients 

On the basis of the route of administration, the North America pharmaceutical excipients market is segmented into oral pharmaceutical excipients, topical pharmaceutical excipients, parenteral pharmaceutical excipients, and other pharmaceutical excipients.

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END-USER

• Pharmaceutical And Biopharmaceutical Companies
• Formulateurs de contrats
• Organismes de recherche et universitaires
• Autres

Sur la base de l'utilisateur final, le marché nord-américain des excipients pharmaceutiques est segmenté en sociétés pharmaceutiques et biopharmaceutiques, formulateurs sous contrat, organismes de recherche et universitaires, etc.

MARCHÉ DES EXCIPIENTS PHARMACEUTIQUES EN AMÉRIQUE DU NORD, PAR CANAL DE DISTRIBUTION

• Appel d'offres direct
• Ventes au détail 
• Autres 

Sur la base du canal de distribution, le marché nord-américain des excipients pharmaceutiques est segmenté en appels d'offres directs, ventes au détail et autres.

Analyse/perspectives régionales du marché des excipients pharmaceutiques en Amérique du Nord

Le marché nord-américain des excipients pharmaceutiques est analysé et des informations sur la taille du marché sont fournies : fonctionnalité, formes posologiques, voie d'administration, utilisateur final et canal de distribution.

Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada et le Mexique.

L'Amérique du Nord domine le marché en raison de la présence d'acteurs clés sur le plus grand marché de consommation avec un PIB élevé. Les États-Unis devraient connaître une croissance en raison de la hausse des progrès technologiques dans le domaine des technologies de l'information dans le domaine de la santé.

L'Amérique du Nord domine le marché. L'augmentation des investissements en R&D devrait stimuler la croissance du marché. Les États-Unis dominent la région Amérique du Nord en raison de la forte présence des principaux acteurs Evonik, Dow, Croda International Plc et autres. Le Royaume-Uni domine l'Europe en raison de la production de masse de médicaments, de la demande croissante des marchés émergents et de l'expansion des industries de la santé. La Chine domine la région Asie-Pacifique en raison de la croissance rapide du marché pharmaceutique associée à l'augmentation de la production de génériques.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des excipients pharmaceutiques en Amérique du Nord

Le paysage concurrentiel du marché des excipients pharmaceutiques en Amérique du Nord fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et la durée de vie du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché des excipients pharmaceutiques en Amérique du Nord.

Certains des principaux acteurs opérant sur le marché des excipients pharmaceutiques en Amérique du Nord sont Kerry Group plc., DFE Pharma, Cargill, Incorporated, Pfanstiehl, Colorcon, MEGGLE GmbH & Co. KG, Omya AG, Peter Greven GmbH & Co. KG, Ashland., Evonik, Dow, Croda International Plc, Roquette Frères., The Lubrizol Corporation, BASF SE, Avantor, Inc., BENEO, entre autres.

SKU-69288